Online Financial Publication, CEO-CFO, Interviews Nutra Pharma Chairman and CEO (OTCBB: NPHC)

Online Financial Publication, CEO-CFO, Interviews Nutra Pharma Chairman and CEO (OTCBB: NPHC) - Nutra Pharma Has Announced That Its Chairman and CEO, Rik J. Deitsch, Was Interviewed by the Senior Editor of CEO-CFO, Lynn Fosse. the Interview, Which Will Be Published in Late-October, Focuses on Nutra Pharma's Launch of Its Pain Reliever, Cobroxin, and the Company's Growth Strategies

Press Release Source: Nutra Pharma Corp.
On Monday October 5, 2009, 9:00 am EDT PLANTATION, Fla.-- Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its Chairman and CEO, Rik J. Deitsch, has completed an interview with leading online financial publication, CEO-CFO.

In the interview, Mr. Deitsch discusses the launch of Cobroxin, an over-the-counter treatment for moderate to severe (Stage 2) chronic pain developed by Nutra Pharma's drug discovery subsidiary, ReceptoPharm. Additionally, Mr. Deitsch also discusses the company's growth strategy as it relates to future potential acquisitions and out-licensing partnerships.
"It is a very exciting time for Nutra Pharma. As the company realizes its first significant revenues through the sale of our drug products, it is more important than ever that we share the story of Nutra Pharma with our investors and the public," explained Mr. Deitsch. "As excitement builds around the launch of Cobroxin and the development of our other leading drug indications, we plan to extend our communication outreach to include consumer-oriented media outlets in addition to financial industry publications," he concluded.

CEO-CFO is a weekly online financial publication that combines news and interviews from key executives at publicly-traded companies and venture capital firms in the United States and abroad. The interview with Mr. Deitsch is scheduled for publication in late-October. Once the interview is published on CEO-CFO, a direct link will be made available on the Nutra Pharma website.

About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
Undiscovered Equities is currently offering a complimentary trial subscription.
To view our newsletter on a complimentary trial basis and take advantage of our other services go to www.undiscoveredequities.com and join our email list on our home page.

disclaimer: http://www.undiscoveredequities.com/disclaimer_np.html

CONTACT: Kevin McKnight
Undiscovered Equities, Inc
Tel: +1 800 404 8982
WWW: http://www.undiscoveredequities.com